-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In April, major listed companies have entered the first quarterly report disclosure period
.
Among them, many traditional Chinese medicine companies have also released performance reports one after another
.
From the current point of view, a large number of traditional Chinese medicine companies have ushered in high growth in the first quarter
.
On April 22, Pien Tze Huang disclosed the performance report for the first quarter of 2022.
The company achieved operating income of 2.
348 billion yuan, a year-on-year increase of 17.
3%; net profit attributable to shareholders of listed companies was 689 million yuan, a year-on-year increase of 21.
93%; attributable to shareholders of listed companies The net profit after deducting non-recurring gains and losses was 676 million yuan, a year-on-year increase of 20.
78%; basic earnings per share were 1.
14 yuan
.
On the same day, China Resources Sanjiu also disclosed its first quarter report.
During the reporting period, the company achieved operating income of 4.
194 billion yuan, a year-on-year increase of 2.
81%; net profit of 839 million yuan, a year-on-year increase of 30.
45%; basic earnings per share of 0.
86 yuan
.
On April 19, Zuoli Pharmaceutical released its 2021 annual report and 2022 first quarter report
.
In 2021, the company will achieve revenue of 1.
457 billion yuan, a year-on-year increase of 33.
60%; net profit will be 179 million yuan, a year-on-year increase of 102.
03%.
The company plans to distribute 10 cash dividends of 2 yuan
.
The first quarterly report of 2022 shows that in the first quarter of 2022, the company achieved revenue of about 439 million yuan, a year-on-year increase of 29.
18%; net profit of about 68.
7467 million yuan, a year-on-year increase of 56.
97%; basic earnings per share of 0.
113 yuan, a year-on-year increase of 56.
94%
.
On April 14, Dong E E Jiao announced its performance forecast for the three months ended March 31, 2022
.
Its announcement shows that the net profit attributable to shareholders of Dong’e Ejiao for the three months ended March 31, 2022 is expected to be approximately RMB 100 million to RMB 120 million (the same period last year: net profit of approximately RMB 61.
65 million), deducting Net profit after non-recurring gains and losses is expected to be approximately RMB 80 million to RMB 100 million (the same period last year: net profit of approximately RMB 44.
66 million) and basic earnings per share are expected to be approximately RMB 0.
16 per share to approximately RMB 0.
19 per share (The same period last year: profit of approximately RMB 0.
10 per share)
.
Judging from the performance forecast, the pre-increase in the performance of the above-mentioned pharmaceutical companies is mainly related to factors such as equity transfer, growth driven by other businesses of subsidiaries, business recovery, and entry of core products into the National Essential Drugs List, which has driven the performance growth of related companies
.
For example, by seizing the opportunity of the country to promote the inheritance, innovation and development of traditional Chinese medicine, Zuoli Pharmaceutical has cultivated a number of core products.
Wuling Capsules, Bailing Tablets and Lingze Tablets have all entered the National Essential Medicine List
.
At present, Zuoli Pharmaceutical's performance is stable and improving, and the revenue scale of its main products Wuling Capsules, Bailing Tablets and Lingze Tablets is growing rapidly; at the same time, with the improvement of profitability, the company has more abundant funds and reduced loan scale , financial costs have also ushered in further reductions
.
In addition to the above companies, a number of Chinese medicine companies have recently disclosed the appointment time for their annual reports.
The overall time period is concentrated from the end of April to the end of May
.
For example, Hongri Pharmaceutical stated on the investor interaction platform on April 20 that the company will disclose the first quarter report on April 29, 2022
.
In general, judging from a series of policies promulgated by the state that are favorable to the development of the traditional Chinese medicine industry, it will create a better growth environment for the traditional Chinese medicine industry; further promote the admission of traditional Chinese medicine to hospitals and broaden the channels for increasing the volume
.
In this context, the industry is generally optimistic that the follow-up market space of the traditional Chinese medicine sector will continue to expand, and the performance of companies in the traditional Chinese medicine sector will continue to grow in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, many traditional Chinese medicine companies have also released performance reports one after another
.
From the current point of view, a large number of traditional Chinese medicine companies have ushered in high growth in the first quarter
.
On April 22, Pien Tze Huang disclosed the performance report for the first quarter of 2022.
The company achieved operating income of 2.
348 billion yuan, a year-on-year increase of 17.
3%; net profit attributable to shareholders of listed companies was 689 million yuan, a year-on-year increase of 21.
93%; attributable to shareholders of listed companies The net profit after deducting non-recurring gains and losses was 676 million yuan, a year-on-year increase of 20.
78%; basic earnings per share were 1.
14 yuan
.
On the same day, China Resources Sanjiu also disclosed its first quarter report.
During the reporting period, the company achieved operating income of 4.
194 billion yuan, a year-on-year increase of 2.
81%; net profit of 839 million yuan, a year-on-year increase of 30.
45%; basic earnings per share of 0.
86 yuan
.
On April 19, Zuoli Pharmaceutical released its 2021 annual report and 2022 first quarter report
.
In 2021, the company will achieve revenue of 1.
457 billion yuan, a year-on-year increase of 33.
60%; net profit will be 179 million yuan, a year-on-year increase of 102.
03%.
The company plans to distribute 10 cash dividends of 2 yuan
.
The first quarterly report of 2022 shows that in the first quarter of 2022, the company achieved revenue of about 439 million yuan, a year-on-year increase of 29.
18%; net profit of about 68.
7467 million yuan, a year-on-year increase of 56.
97%; basic earnings per share of 0.
113 yuan, a year-on-year increase of 56.
94%
.
On April 14, Dong E E Jiao announced its performance forecast for the three months ended March 31, 2022
.
Its announcement shows that the net profit attributable to shareholders of Dong’e Ejiao for the three months ended March 31, 2022 is expected to be approximately RMB 100 million to RMB 120 million (the same period last year: net profit of approximately RMB 61.
65 million), deducting Net profit after non-recurring gains and losses is expected to be approximately RMB 80 million to RMB 100 million (the same period last year: net profit of approximately RMB 44.
66 million) and basic earnings per share are expected to be approximately RMB 0.
16 per share to approximately RMB 0.
19 per share (The same period last year: profit of approximately RMB 0.
10 per share)
.
Judging from the performance forecast, the pre-increase in the performance of the above-mentioned pharmaceutical companies is mainly related to factors such as equity transfer, growth driven by other businesses of subsidiaries, business recovery, and entry of core products into the National Essential Drugs List, which has driven the performance growth of related companies
.
For example, by seizing the opportunity of the country to promote the inheritance, innovation and development of traditional Chinese medicine, Zuoli Pharmaceutical has cultivated a number of core products.
Wuling Capsules, Bailing Tablets and Lingze Tablets have all entered the National Essential Medicine List
.
At present, Zuoli Pharmaceutical's performance is stable and improving, and the revenue scale of its main products Wuling Capsules, Bailing Tablets and Lingze Tablets is growing rapidly; at the same time, with the improvement of profitability, the company has more abundant funds and reduced loan scale , financial costs have also ushered in further reductions
.
In addition to the above companies, a number of Chinese medicine companies have recently disclosed the appointment time for their annual reports.
The overall time period is concentrated from the end of April to the end of May
.
For example, Hongri Pharmaceutical stated on the investor interaction platform on April 20 that the company will disclose the first quarter report on April 29, 2022
.
In general, judging from a series of policies promulgated by the state that are favorable to the development of the traditional Chinese medicine industry, it will create a better growth environment for the traditional Chinese medicine industry; further promote the admission of traditional Chinese medicine to hospitals and broaden the channels for increasing the volume
.
In this context, the industry is generally optimistic that the follow-up market space of the traditional Chinese medicine sector will continue to expand, and the performance of companies in the traditional Chinese medicine sector will continue to grow in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
